When Combined with Colistin, an Otherwise Ineffective Rifampicin-Linezolid Combination Becomes Active in and .

Eva Armengol, Teresa Asunción, Miguel Viñas, Josep Maria Sierra
Author Information
  1. Eva Armengol: Laboratory of Molecular Microbiology and Antimicrobials, Department of Pathology and Experimental Therapeutics, School of Medicine. Institut d'Investigacions biomèdiques de Bellvitge (IDIBELL), University of Barcelona, 08907 L'Hospitalet, Barcelona, Spain.
  2. Teresa Asunción: Laboratory of Molecular Microbiology and Antimicrobials, Department of Pathology and Experimental Therapeutics, School of Medicine. Institut d'Investigacions biomèdiques de Bellvitge (IDIBELL), University of Barcelona, 08907 L'Hospitalet, Barcelona, Spain.
  3. Miguel Viñas: Laboratory of Molecular Microbiology and Antimicrobials, Department of Pathology and Experimental Therapeutics, School of Medicine. Institut d'Investigacions biomèdiques de Bellvitge (IDIBELL), University of Barcelona, 08907 L'Hospitalet, Barcelona, Spain.
  4. Josep Maria Sierra: Laboratory of Molecular Microbiology and Antimicrobials, Department of Pathology and Experimental Therapeutics, School of Medicine. Institut d'Investigacions biomèdiques de Bellvitge (IDIBELL), University of Barcelona, 08907 L'Hospitalet, Barcelona, Spain.

Abstract

The synergistic action of colistin, with two antibiotics active in Gram-positive bacteria but unable to kill gram negatives (linezolid and rifampicin), was investigated, since triple combinations are emerging as a tool to overtake multidrug resistance. Checkerboard determinations demonstrated that, when combined with colistin, the combination of linezolid and rifampicin turns active in multidrug-resistant and . Thus, the presence of sublethal concentrations of colistin resulted in a strongly synergistic interaction between these two drugs. Moreover, the minimum inhibitory concentrations of linezolid-rifampicin combinations in the presence of colistin were lower than the maximal concentrations of these antimicrobials ain blood. These findings suggest the use of this triple combination as an effective treatment of multidrug-resistant (MDR) bacterial infections.

Keywords

References

  1. Ann Clin Microbiol Antimicrob. 2017 Nov 25;16(1):76 [PMID: 29178957]
  2. J Antimicrob Chemother. 2007 Jun;59(6):1261-4 [PMID: 16971414]
  3. J Antimicrob Chemother. 2017 May 1;72(5):1415-1420 [PMID: 28333347]
  4. Int J Antimicrob Agents. 2016 Dec;48(6):607-613 [PMID: 27865626]
  5. Expert Opin Biol Ther. 2017 Jun;17(6):663-676 [PMID: 28368216]
  6. Diagn Microbiol Infect Dis. 2017 Aug;88(4):355-360 [PMID: 28583381]
  7. J Infect Dis. 1980 Oct;142(4):602-7 [PMID: 7441019]
  8. Diagn Microbiol Infect Dis. 2016 Oct;86(2):184-9 [PMID: 27475960]
  9. Infect Dis Ther. 2014 Dec;3(2):69-81 [PMID: 25475412]
  10. J Antimicrob Chemother. 2019 Feb 1;74(2):387-394 [PMID: 30376071]
  11. Res Microbiol. 2016 Apr;167(3):215-21 [PMID: 26723273]
  12. J Antimicrob Chemother. 1984 Oct;14(4):359-66 [PMID: 6501129]
  13. Rev Soc Bras Med Trop. 2014 Jul;47(4):451-6 [PMID: 25229285]
  14. Infect Drug Resist. 2019 Jul 11;12:2031-2038 [PMID: 31372011]
  15. Antimicrob Agents Chemother. 2018 Nov 26;62(12): [PMID: 30224527]
  16. Antimicrob Agents Chemother. 2016 Jan 04;60(3):1717-24 [PMID: 26729502]
  17. Antimicrob Agents Chemother. 2014;58(3):1757-62 [PMID: 24395223]
  18. Nat Rev Microbiol. 2005 Mar;3(3):238-50 [PMID: 15703760]
  19. Int J Antimicrob Agents. 2019 Jun;53(6):855-858 [PMID: 30836109]
  20. Lancet Infect Dis. 2019 Jan;19(1):56-66 [PMID: 30409683]
  21. Molecules. 2016 Sep 12;21(9): [PMID: 27626405]
  22. J Antimicrob Chemother. 2019 Jan 1;74(1):87-95 [PMID: 30346547]
  23. J Antimicrob Chemother. 2018 Dec 1;73(12):3385-3390 [PMID: 30215733]
  24. Int J Antimicrob Agents. 2019 Jun;53(6):868-872 [PMID: 30447380]
  25. Curr Med Res Opin. 2015 Apr;31(4):707-21 [PMID: 25697677]
  26. Microb Drug Resist. 2014 Dec;20(6):550-4 [PMID: 25055029]

Grants

  1. BARNAPA/Fundació la Marató de TV3

Word Cloud

Created with Highcharts 10.0.0colistincombinationsmultidrug-resistantconcentrationssynergistictwoactivebacterialinezolidrifampicintriplecombinationpresenceMDRactionantibioticsGram-positiveunablekillgramnegativesinvestigatedsinceemergingtoolovertakemultidrugresistanceCheckerboarddeterminationsdemonstratedcombinedturnsThussublethalresultedstronglyinteractiondrugsMoreoverminimuminhibitorylinezolid-rifampicinlowermaximalantimicrobialsainbloodfindingssuggestuseeffectivetreatmentbacterialinfectionsCombinedColistinOtherwiseIneffectiveRifampicin-LinezolidCombinationBecomesActiveantibioticsynergism

Similar Articles

Cited By